Physician profile
Danny R Thomas
NPI 1174687651
$681.06
in general payments reported to CMS, 2019-2025
11 companies · $35.23 in 2025
The $35.23 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $172 · 2021: $15.30 · 2025: $35.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $211.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $140.84 | 2019-2020 | |
| Allergan, INC. | $113.12 | 2020 | |
| Janssen Biotech, INC. | $61.41 | 2019 | |
| Mayne Pharma Commercial LLC | $38.88 | 2020 | |
| Medline Industries LP | $35.23 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.26 | 2019 | |
| Glaxosmithkline, LLC. | $17.83 | 2019 | |
| Abbvie INC. | $15.30 | 2021 | |
| Merck Sharp & Dohme LLC | $13.11 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.